LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product for the treatment of facial lipoatrophy. In addition, the company offers various therapeutic products for the treatment of oncology, and neurological diseases and disorders, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Date	Price Target	Rating	Analyst
8/20/2024	$4.00	Buy	Craig Hallum
11/2/2022	$5.00	Outperform	Robert W. Baird
6/14/2022	$4.00	Buy	B. Riley Securities
8/19/2021	$8.00	Outperform	Noble Capital Markets

Lineage Cell Therapeutics Inc.

Recent Analyst Ratings for Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc. Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Craig Hallum initiated coverage on Lineage Cell Therapeutics with a new price target

Robert W. Baird initiated coverage on Lineage Cell Therapeutics with a new price target

B. Riley Securities initiated coverage on Lineage Cell Therapeutics with a new price target

Noble Capital Markets initiated coverage on Lineage Cell Therapeutics with a new price target

Cantor Fitzgerald initiated coverage on Lineage Cell Therapeutics with a new price target

Lineage Cell Therapeutics Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by President and CEO Culley Brian M

SEC Form 4 filed by Chief Financial Officer Howe Jill Ann

SEC Form 4 filed by General Counsel and Secretary Samuel George A. Iii

General Counsel Samuel George A. Iii converted options into 6,076 shares and covered exercise/tax liability with 2,440 shares, increasing direct ownership by 16% to 25,820 units (SEC Form 4)

President and CEO Culley Brian M converted options into 31,249 shares and covered exercise/tax liability with 12,547 shares, increasing direct ownership by 10% to 213,544 units (SEC Form 4)

Director Broadwood Partners, L.P. bought $6,000,000 worth of shares (7,894,737 units at $0.76) (SEC Form 4)

Chief Financial Officer Howe Jill Ann bought $8,850 worth of shares (15,000 units at $0.59), increasing direct ownership by 143% to 25,500 units (SEC Form 4)

General Counsel Samuel George A. Iii bought $9,000 worth of shares (15,000 units at $0.60), increasing direct ownership by 209% to 22,184 units (SEC Form 4)

Director Mulroy Michael H. bought $22,640 worth of shares (40,000 units at $0.57), increasing direct ownership by 15% to 298,555 units (SEC Form 4)

President and CEO Culley Brian M bought $24,000 worth of shares (40,000 units at $0.60), increasing direct ownership by 26% to 194,842 units (SEC Form 4)